- Home
- CAPT vs LPCN Comparison
CAPT vs LPCN Comparison
Compare CAPT & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- LPCN
- Stock Information
- Founded
- CAPT 2005
- LPCN 1997
- Country
- CAPT South Korea
- LPCN United States
- Employees
- CAPT N/A
- LPCN N/A
- Industry
- CAPT Blank Checks
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- LPCN Health Care
- Exchange
- CAPT Nasdaq
- LPCN Nasdaq
- Market Cap
- CAPT 41.9M
- LPCN 36.8M
- IPO Year
- CAPT N/A
- LPCN N/A
- Fundamental
- Price
- CAPT $0.68
- LPCN $4.86
- Analyst Decision
- CAPT
- LPCN Strong Buy
- Analyst Count
- CAPT 0
- LPCN 1
- Target Price
- CAPT N/A
- LPCN $10.00
- AVG Volume (30 Days)
- CAPT 334.4K
- LPCN 28.2K
- Earning Date
- CAPT 01-01-0001
- LPCN 11-07-2024
- Dividend Yield
- CAPT N/A
- LPCN N/A
- EPS Growth
- CAPT N/A
- LPCN N/A
- EPS
- CAPT N/A
- LPCN N/A
- Revenue
- CAPT $17,389,944.00
- LPCN $7,922,926.00
- Revenue This Year
- CAPT N/A
- LPCN N/A
- Revenue Next Year
- CAPT N/A
- LPCN N/A
- P/E Ratio
- CAPT N/A
- LPCN N/A
- Revenue Growth
- CAPT 84.70
- LPCN N/A
- 52 Week Low
- CAPT $0.65
- LPCN $2.44
- 52 Week High
- CAPT $7.92
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- CAPT 36.38
- LPCN 50.88
- Support Level
- CAPT $0.65
- LPCN $4.70
- Resistance Level
- CAPT $0.99
- LPCN $5.28
- Average True Range (ATR)
- CAPT 0.11
- LPCN 0.32
- MACD
- CAPT 0.01
- LPCN 0.04
- Stochastic Oscillator
- CAPT 8.70
- LPCN 69.53
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.